BOBBI LUTTRELL: Open Payments
NPI 1366969271 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$449 in 24 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $449
Food & beverage: $449
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $105 |
| AstraZeneca Pharmaceuticals LP | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $56 |
| Dexcom, Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Exact Sciences Corporation | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $20 |
| Novo Nordisk Inc | 1 | $19 |
Products named: VRAYLAR, FANAPT, CAPLYTA, AIRSUPRA, Dexcom G6 Transmitter, Auvelity, Cologuard Collection Kit, REXULTI.
Industry payments across IN — which companies pay providers there.
